INS-IGF2

Across TCGA pan-cancer cohorts, INS-IGF2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated INS-IGF2 data layer compared with 12 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher INS-IGF2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated INS-IGF2 expression acts as an unfavorable survival marker.

PRAD are the cancer types where INS-IGF2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

INS-IGF2–PRAD (DFS)

Open the PRAD breakdown →